GlassScriptPhysician profile
Shaun S Daneshrad
NPI 1962452565
$5,291.50
in general payments reported to CMS, 2019-2025
27 companies · $831 in 2025
The $831 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $563 · 2021: $1,042 · 2022: $891 · 2023: $783 · 2024: $733 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $846.95 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $637.15 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $585.45 | 2019-2025 | Farxiga |
| Edwards Lifesciences Corporation | $469.92 | 2020-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $391.04 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.30 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $281.31 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.44 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.15 | 2022-2024 | Xifaxan |
| Amarin Pharma, INC. | $178.59 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $166.50 | 2022-2024 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $146.13 | 2019-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $106.40 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.72 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $69.18 | 2022-2025 | Wegovy, Ozempic |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $68.25 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $61.83 | 2021-2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $57.36 | 2019-2024 | Bodyguardian |
| Heartflow, INC. | $54.34 | 2023-2025 | Ffrct |
| Baxter Healthcare | $42.50 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $40.61 | 2021-2025 | Nexletol |
| Alexion Pharmaceuticals, INC. | $34.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $33.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $31.39 | 2024 | Evkeeza |
| Janssen Scientific Affairs, LLC | $24.33 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.17 | 2021 | |
| Preventice Services, LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Daneshrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.